Gemzar Proves a Point
This article was originally published in RPM Report
Executive Summary
FDA approval of Eli Lilly's oncology drug Gemzar for ovarian cancer against the recommendation of the agency's advisory committee shows FDA is serious about progression-free survival as a primary clinical endpoint.